VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

Revolution Medicines Executive Compensation (FY25)

RVMD · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Mark Goldsmith
Median of the other named officers
$4,821,057
5 officers, excluding the chief executive
Latest say-on-pay support
=
June 18, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Revolution Medicines

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
Data as of November 5, 2026Latest filing (8-K): June 22, 2026
12 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Revolution Medicines brief$500Get the executive brief
Velarion Intel, one year, every company
346 figures on this page: 341 cited to the filing that reported them, 5 calculated from figures it prints. See the citations

More on Revolution Medicines

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Mark Goldsmith: $10,079,491 → $14,672,390 (45.6% higher)
CEO pay ratio: 28:1 → 34:1 (21.4% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Revolution Medicines' chief executive and what were they paid?
Total compensation for Mark Goldsmith, President and Chief Executive Officer, came to $14,672,390 in fiscal 2025. Goldsmith's total moved 45.6% higher from the $10,079,491 reported for fiscal 2024.
What was Revolution Medicines' say-on-pay result?
Shareholders supported the say-on-pay proposal with 96.5% of votes cast for or against in favor at the meeting held June 18, 2026 for fiscal 2025.
Which companies are in Revolution Medicines' peer group?
The disclosed peer group includes Apellis Pharmaceuticals, Arrowhead Pharmaceuticals, Arvinas, Blueprint Medicines and Cerevel Therapeutics, among others.
What is Revolution Medicines' chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 34:1, against median employee compensation of $433,964.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Mark Goldsmith
President and Chief Executive Officer
◇—◇◇◇—◇◇
Steve FRCPath
President, Research and Development
◇—◇◇◇—◇◇
Margaret Horn
Chief Operating Officer
◇—◇◇◇—◇◇
Jack Anders
Chief Financial Officer
◇—◇◇◇—◇◇
Sc.D. Xiaolin Wang
Executive Vice President, Development
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Mark Goldsmith
President and Chief Executive Officer
◇—◇◇◇—◇◇
Steve FRCPath
President, Research and Development
◇—◇◇◇—◇◇
Margaret Horn
Chief Operating Officer
◇—◇◇◇—◇◇
Sc.D. Xiaolin Wang
Executive Vice President, Development
◇—◇◇◇—◇◇
Jack Anders
Chief Financial Officer
◇—◇◇◇—◇◇
Jeffrey Cislini
General Counsel and Secretary
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Mark Goldsmith
President and Chief Executive Officer
◇—◇◇◇—◇◇
Steve FRCPath
President, Research and Development
◇—◇◇◇—◇◇
Margaret Horn
Chief Operating Officer
◇—◇◇◇—◇◇
Jack Anders
Chief Financial Officer
◇—◇◇◇—◇◇
Sc.D. Xiaolin Wang
Executive Vice President, Development
◇—◇◇◇—◇◇
Jeffrey Cislini
General Counsel and Secretary
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Mark Goldsmith
President and Chief Executive Officer
◇—◇◇◇—◇◇
Stephen Kelsey
President, Research and Development
◇—◇◇◇—◇◇
Stephen FRCPath
President, Research and Development
◇—◇◇◇—◇◇
Margaret Horn
Chief Operating Officer
◇—◇◇◇—◇◇
Jeffrey Cislini
General Counsel and Secretary
◇—◇◇◇—◇◇
Jack Anders
Chief Financial Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Jack AndersRSU◇——◇——◇
Jack AndersOPTION◇——◇—◇◇
Jeffrey CisliniRSU◇——◇——◇
Jeffrey CisliniOPTION◇——◇—◇◇
Margaret HornOPTION◇——◇—◇◇
Margaret HornRSU◇——◇——◇
Mark A. GoldsmithRSU◇——◇——◇
Mark A. GoldsmithOPTION◇——◇—◇◇
Stephen M. KelseyRSU◇——◇——◇
Stephen M. KelseyOPTION◇——◇—◇◇
Steve FRCPathRSU◇——◇——◇
Steve FRCPathOPTION◇——◇—◇◇
Fiscal 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Mark GoldsmithOption◇—◇3/1/2035
Option◇—◇3/1/2034
Option◇—◇3/1/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/1/2032
RSU◇◇——
Stephen KelseyOption◇—◇3/1/2035
Option◇—◇3/1/2034
Option◇—◇3/1/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/1/2032
RSU◇◇——
Margaret HornOption◇—◇3/1/2035
Option◇—◇3/1/2034
Option◇—◇3/1/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/1/2032
RSU◇◇——
Jeffrey CisliniOption◇—◇3/1/2035
Option◇—◇3/1/2034
Option◇—◇3/1/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇9/1/2032
Option◇—◇3/1/2032
RSU◇◇——
RSU◇◇——
Jack AndersOption◇—◇3/1/2035
Option◇—◇3/1/2034
Option◇—◇3/1/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇9/1/2032
Option◇—◇3/1/2032
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Jack Anders
Chief Financial Officer · Severance agreement
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Jeffrey Cislini
General Counsel and Secretary · Employment agreement
Severance multiple◇
Severance cash amount◇
Change-in-control multiple◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇
Margaret Horn
Chief Operating Officer · Amended agreement
Severance multiple◇
Benefits continuation◇
Stephen Kelsey
President, Research and Development · Amended agreement
Severance multiple◇
Benefits continuation◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Alexis Borisy
Lead independent director
◇◇◇———◇
Lorence Kim, M.D
◇◇◇———◇
Elizabeth McKee Anderson
◇◇◇———◇
Flavia Borellini, Ph.D
◇◇◇———◇
Sushil Patel, Ph.D
◇◇◇———◇
Sandra J. Horning, M.D
◇◇◇———◇
Frank K. Clyburn Jr
◇◇◇———◇
Barbara Weber, M.D
◇—————◇
Thilo Schroeder, Ph.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options and RSUs.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Apellis Pharmaceuticals APLS
  • Arrowhead Pharmaceuticals ARWR
  • Arvinas ARVN
  • Blueprint Medicines BPMC
  • Cerevel Therapeutics CERE
  • CRISPR Therapeutics CRSP
  • Cytokinetics CYTK
  • Denali Therapeutics DNLI
  • Intellia Therapeutics NTLA
  • Intra-Cellular Therapeutics ITCI
  • Ionis Pharmaceuticals IONS
  • Krystal Biotech KRYS
  • Madrigal Pharmaceuticals MDGL
  • Nuvalent NUVL
  • Roivant Sciences ROIV
  • SpringWorks Therapeutics SWTX
  • Vaxcyte PCVX

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 18, 2026=◇◇◇
2024June 26, 2025=◇◇◇
2023June 20, 2024=◇◇◇
2022June 8, 2023=◇◇◇
2021June 16, 2022=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Tell me when Revolution Medicines files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Revolution Medicines disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Revolution Medicines sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Revolution Medicines' disclosed peer group is defensible, who names Revolution Medicines back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
346 figures on this page: 341 cited to the filing that reported them, 5 calculated from figures it prints.
341 cited to the filing
5 calculated from the filing

Documents cited

  1. 0001193125-26-276718
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001193125-26-182453
    2025 Summary Compensation Table · DIRECTOR COMPENSATION · EXECUTIVE COMPENSATION TABLES · Grants of Plan-Based Awards
  7. 0001193125-25-151254
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001193125-25-103947
    EXECUTIVE COMPENSATION TABLES
  9. 0001193125-24-166939
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0000950170-24-048380
    EXECUTIVE COMPENSATION TABLES
  11. 0001193125-23-164446
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001193125-22-177651
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Revolution Medicines executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/RVMD (accessed 2026).
Short form: data: Velarion

The paid brief for Revolution Medicines

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
12 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Revolution Medicines and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Revolution Medicines discloses

The companies named in RVMD's own disclosed peer group.

Apellis PharmaceuticalsArrowhead PharmaceuticalsArvinasBlueprint MedicinesCerevel TherapeuticsCRISPR TherapeuticsCytokineticsDenali TherapeuticsIntellia TherapeuticsIntra-Cellular TherapeuticsIonis PharmaceuticalsKrystal BiotechMadrigal PharmaceuticalsNuvalentRoivant SciencesSpringWorks TherapeuticsVaxcyte

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy